Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Merestinib Monotherapy or Combination in Japanese Patients with Advanced Cancer
NCT03027284Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of merestinib in solid tumor (advanced stage), metastatic cancer, non-Hodgkin lymphoma (NHL) and 3 more (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Dose-Limiting Toxicities. Started Feb 2017; status: completed.
02
Drugs
merestinib
03
Conditions
solid tumor (advanced stage)metastatic cancernon-Hodgkin lymphoma (NHL)biliary tract carcinoma (BTC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT03027284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03027284.